BIOKÉ Webshop

Forgot password?Login

No need to login to view prices!

No account?

Enjoy the advantages of a BIOKÉ webshop account.

Invalid login

Your credentials are incorrect or you are trying to login with a non-existing webshop account. Our website shows product prices without login! Therefore webshop accounts that were only used to view prices have been deleted.

Please create a new account with your shipping and billing details if you would like to be able to order or view your discount.


Webshop under construction

The BIOKÉ webshop is closed until 14:00 January 2nd, 2020. We wish you a successful 2020!

Forgot your password?

Don't worry. Enter your username and we will send you a link to reset your password if an associated user is found.

Need help?

Have trouble resetting your password? Contact us and we will help you.

You've got mail

You will receive an e-mail containing a link to start the recovery procedure within minutes.


Change password

Change your password to something secure.

Success

Your password has been changed.


Password sent

You will receive an e-mail from us containing your new password in the coming minutes.

Please change your password to something memorable and secure upon logging in.


Welcome

Sign out

Agilent Completes Acquisition of ACEA Biosciences


SANTA CLARA, Calif., November 14, 2018 - Agilent Technologies Inc. (NYSE: A) today announced it has completed the acquisition of ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis tools, for $250 million in cash. This acquisition brings together two pioneers in cellular function and metabolism measurements focused on real-time, live cell analyses.

ACEA has developed two ground-breaking platforms that are complementary to Agilent's current portfolio. The ACEA xCELLigence® RTCA technology is a unique impedance platform for label-free, real-time cellular function measurements used in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. This technology is complemented by the introduction in recent years of the NovoCyte® and NovoCyte Quanteon™ portfolio of high performance bench top flow cytometry systems.

ACEA also markets a clinical configuration of the NovoCyte platform, currently commercialized in China. This provides a unique opportunity in combination with Agilent's Reagent Partnership business within Agilent's Diagnostics and Genomics Group which provides reagents for flow cytometry. "The Agilent and ACEA teams are united by a common goal to provide the most innovative high-performance solutions for cell analysis," said Todd Christian, Vice President & General Manager of Agilent's Cell Analysis Division. "We are excited for the opportunities we have as a newly combined team to provide the most advanced tools for scientists performing cell analysis workflows."

ACEA is Agilent's second acquisition this year in the cell analysis space. In January, Agilent acquired Luxcel Biosciences, a developer of real-time fluorescence plate-reader based in vitro cell assay kits. Cell analysis is a key area of strategic focus for Agilent. ACEA was founded in 2002 and has its headquarters in San Diego and a large manufacturing and R&D footprint in Hangzhou, China. More than 2,500 ACEA instruments have been placed globally and have been used in more than 1,800 peer-reviewed publications.

 

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,500 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom.

Product has been added to your cart.